480 related articles for article (PubMed ID: 18954042)
1. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
[TBL] [Abstract][Full Text] [Related]
2. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
[TBL] [Abstract][Full Text] [Related]
3. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Seo HJ; Kim MJ; Song KS; Lee SH; Jung ME; Kim MS; Park HJ; Yoo J; Chang CH; Kim J; Lee J
Future Med Chem; 2009 Aug; 1(5):947-67. PubMed ID: 21426091
[TBL] [Abstract][Full Text] [Related]
4. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.
Kim JY; Seo HJ; Lee SH; Jung ME; Ahn K; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Jan; 19(1):142-5. PubMed ID: 19022666
[TBL] [Abstract][Full Text] [Related]
5. Pentacycle derivatives as cannabinoid CB1 receptor ligands.
Lee SH; Seo HJ; Kim MJ; Kang SY; Lee SH; Ahn K; Lee M; Han HK; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Dec; 19(23):6632-6. PubMed ID: 19850473
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
[TBL] [Abstract][Full Text] [Related]
7. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
Lee J; Seo HJ; Lee SH; Kim J; Jung ME; Lee SH; Song KS; Lee J; Kang SY; Kim MJ; Kim MS; Son EJ; Lee M; Han HK
Bioorg Med Chem; 2010 Sep; 18(17):6377-88. PubMed ID: 20673729
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
[TBL] [Abstract][Full Text] [Related]
13. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.
Lange JH; van Stuivenberg HH; Veerman W; Wals HC; Stork B; Coolen HK; McCreary AC; Adolfs TJ; Kruse CG
Bioorg Med Chem Lett; 2005 Nov; 15(21):4794-8. PubMed ID: 16140010
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist.
Hung MS; Chang CP; Li TC; Yeh TK; Song JS; Lin Y; Wu CH; Kuo PC; Amancha PK; Wong YC; Hsiao WC; Chao YS; Shia KS
ChemMedChem; 2010 Sep; 5(9):1439-43. PubMed ID: 20652930
[No Abstract] [Full Text] [Related]
15. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
Lange JH; Coolen HK; van Stuivenberg HH; Dijksman JA; Herremans AH; Ronken E; Keizer HG; Tipker K; McCreary AC; Veerman W; Wals HC; Stork B; Verveer PC; den Hartog AP; de Jong NM; Adolfs TJ; Hoogendoorn J; Kruse CG
J Med Chem; 2004 Jan; 47(3):627-43. PubMed ID: 14736243
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
Silvestri R; Cascio MG; La Regina G; Piscitelli F; Lavecchia A; Brizzi A; Pasquini S; Botta M; Novellino E; Di Marzo V; Corelli F
J Med Chem; 2008 Mar; 51(6):1560-76. PubMed ID: 18293908
[TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
18. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
Lange JH; van der Neut MA; den Hartog AP; Wals HC; Hoogendoorn J; van Stuivenberg HH; van Vliet BJ; Kruse CG
Bioorg Med Chem Lett; 2010 Mar; 20(5):1752-7. PubMed ID: 20137935
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.
Dow RL; Carpino PA; Hadcock JR; Black SC; Iredale PA; DaSilva-Jardine P; Schneider SR; Paight ES; Griffith DA; Scott DO; O'Connor RE; Nduaka CI
J Med Chem; 2009 May; 52(9):2652-5. PubMed ID: 19351113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
